US5158536A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lung cancer hyperthermia via ultrasound and/or convection with perfiuorochemical liquids
Assignee: Temple University
•
Filing: 1990-03-19
•
Granted: 1992-10-27
•
Expires: 2010-03-19
Abstract
Abstract A hyperthermic treatment of lung cancer, by temporarily filling with a liquid medium preselected pulmonary air passages adjoining pulmonary tissues containing malignant cells, circulating exogenously heated liquid medium at from about 41° to ab This invention was made with government support under Small Business Innovation Research Program Grant No. 1 R43 CA48611-01 awarded by the Public Health Service, Department of Health and Human Services. The government has certain rights in the invention.
Inventors
- 👤 K. Michael Sekins
- 👤 Thomas H. Shaffer
- 👤 Marla R. Wolfson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:46
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026; A61F; A61F7/00; A61F7/12; A61F7/123; A61M; A61M16/00; A61M16/0003; A61M16/0006; A61M16/04; A61M16/0402; A61M16/0404; A61M16/0434; A61M16/0436; A61M16/0438; A61M16/0443; A61M16/0454; A61M16/0459; A61M16/0463; A61M16/0475; A61M16/0477; A61M16/0479; A61M16/0486; A61N; A61N7/00; A61N7/02; A61N7/022; B; B06; B06B; B06B1/00; B06B1/02; B06B1/06; B06B1/0607; B06B1/0622; B06B1/0633; A61B; A61B17/00; A61B17/22; A61B2017/22051; A61B2017/22054; A61B18/00; A61B2018/00005; A61B2018/00011; A61F2007/0054; A61M15/00; A61M2202/00; A61M2202/04; A61M2202/0468; A61M2202/0476; A61M2205/00; A61M2205/33; A61M2205/3368
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
77 words
A hyperthermic treatment of lung cancer, comprising the steps of: temporarily filling with a liquid medium preselected pulmonary air passages adjoining pulmonary tissues comprising malignant cells, heating the adjoining pulmonary tissues comprising the malignant cells to a temperature in the range of from about 41° to about 50° C. for a period of time by transmitting ultrasound through the liquid-filled pulmonary air passages, and thereafter removing the liquid medium from the pulmonary air passages of the patient.
Claim 2
Dependent Claim
77 words
A hyperthermic treatment of lung cancer, comprising the steps of: temporarily filling with a liquid medium preselected pulmonary air passages adjoining pulmonary tissues comprising malignant cells, heating the adjoining pulmonary tissues comprising the malignant cells to a temperature in the range of from about 41° to about 50° C. for a period of time by transmitting ultrasound through the liquid-filled pulmonary air passages, and thereafter removing the liquid medium from the pulmonary air passages of the patient.
Claim 3
Dependent Claim
21 words
The hyperthermic treatment of claim 1, wherein the temperature is in the range of from about 42° to about 45° C.
Claim 4
Dependent Claim
13 words
The hyperthermic treatment of claim 1, wherein the liquid medium is a perfluorochemical.
Claim 5
Dependent Claim
26 words
The hyperthermic treatment of claim 3, wherein the perfluorochemical is characterized by an average molecular weight in the range of from about 400 to about 500.
Claim 6
Dependent Claim
26 words
The hyperthermic treatment of claim 4, wherein the perfluorochemical is characterized by an average molecular weight in the range of from about 400 to about 460.
Claim 7
Dependent Claim
26 words
The hyperthermic treatment of claim 5, wherein the perfluorochemical is characterized by an average molecular weight in the range of from about 420 to about 460.
Claim 8
Dependent Claim
92 words
The hyperthermic treatment of claim 3, wherein the perfluorochemical is characterized by having: viscosity less than about 5 CP at 25° C., density at less than about 2.0 g/cm 3 at 25° C., boiling point greater than about 75° C., vapor pressure in the range of from about 25 Torr to about 100 Torr, acoustic impedance in the range of from about 0.8 to about 1.6 MegaRayls at 37° C., acoustic attenuation less than about 1.2 dB/cm at 1.0 MHz, 45° C., and an acoustic intensity of about 3 W/cm 2 .
Claim 9
Dependent Claim
21 words
The hyperthermic treatment of claim 7, wherein the perfluorochemical is characterized by O 2 solubility greater than about 40 ml/100 ml.
Claim 10
Dependent Claim
17 words
The hyperthermic treatment of claim 5, wherein the perfluorochemical is selected from among FC-75, RM-101, and perfluorodecalin.
Claim 11
Dependent Claim
23 words
The hyperthermic treatment of claim 3, wherein the ultrasound is in the frequency range of from about 250 KHz to about 3 MHz.
Claim 12
Dependent Claim
23 words
The hyperthermic treatment of claim 10, wherein the ultrasound is in the frequency range of from about 500 KHz to about 2 MHz.
Claim 13
Dependent Claim
23 words
The hyperthermic treatment of claim 10, wherein the ultrasound is in the frequency range of from about 250 KHz to about 1.5 MHz.
Claim 14
Dependent Claim
13 words
The hyperthermic treatment of claim 1, wherein the liquid medium is physiological saline.
Claim 15
Dependent Claim
23 words
The hyperthermic treatment of claim 13, wherein the ultrasound is in the frequency range of from about 250 KHz to about 3 MHz.
Claim 16
Dependent Claim
23 words
The hyperthermic treatment of claim 14, wherein the ultrasound is in the frequency range of from about 500 KHz to about 3 MHz.
Claim 17
Dependent Claim
23 words
The hyperthermic treatment of claim 15, wherein the ultrasound is in the frequency range of from about 750 KHz to about 3 MHz.
Claim 18
Dependent Claim
21 words
The hyperthermic treatment of claim 1, wherein the ultrasound is produced by a transducer disposed within the liquid-filled pulmonary air passages.
Claim 19
Dependent Claim
22 words
The hyperthermic treatment of claim 1, wherein the ultrasound is produced by a transducer disposed exogenous to the liquid-filled pulmonary air passages.
Claim 20
Dependent Claim
18 words
The hyperthermic treatment of claim 18, wherein the ultrasound is transmitted through an intercostal space of the patient.
Claim 21
Dependent Claim
21 words
The hyperthermic treatment of claim 1, wherein the filling of the liquid-filled pulmonary air passages is monitored by diagnostic ultrasonic imaging.
Claim 22
Dependent Claim
15 words
The hyperthermic treatment of claim 3, wherein the perfluorochemical is degassed during the filling step.
Claim 23
Dependent Claim
18 words
The hyperthermic treatment of claim 21, wherein the perfluorochemical is substantially degassed at least during the filling step.
Claim 24
Dependent Claim
19 words
The hyperthermic treatment of claim 1, further comprising, during the heating step, irradiating the malignant cells with ionizing radiation.
Claim 25
Dependent Claim
21 words
The hyperthermic treatment of claim 23, further comprising the step of oxygenating the liquid medium in the liquid-filled pulmonary air passages.
Claim 26
Dependent Claim
41 words
The hyperthermic treatment of claim 24, wherein ultrasound in the frequency range of from about 2 MHz to about 3 MHz is transmitted through the pulmonary air passages filled with a perfluorochemical oxygenated to no more than about 75 percent saturation.
Claim 27
Dependent Claim
41 words
The hyperthermic treatment of claim 24, wherein ultrasound in the frequency range of from about 250 KHz to about 1.5 MHz is transmitted through the pulmonary air passages filled with a perfluorochemical oxygenated to no more than about 50 percent saturation.
Claim 28
Dependent Claim
14 words
The hyperthermic treatment of claim 1, wherein the liquid medium comprises a therapeutic agent.
Claim 29
Dependent Claim
21 words
The hyperthermic treatment of claim 1, further comprising the step of introducing a chemotherapeutic agent into the liquid-filled pulmonary air passages.
Claim 30
Dependent Claim
25 words
The hyperthermic treatment of claim 1, wherein the liquid medium is circulated during the heating step between the liquid-filled air passages and an exogenous reservoir.
References Cited (Backward Citations)
US2936761A
Cited
US3358677A
Cited
US4046139A
Cited
US4233984A
Cited
US4315514A
Cited
US4323056A
Cited
US4657532A
Cited
WO1989004035A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-10-27 | 1996-04-27 | 1996-10-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-10-27 | 2000-04-27 | 2000-10-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-10-27 | 2004-04-27 | 2004-10-27 | $7700.00 | Window Closed / Lapsed |